Back to Journals » OncoTargets and Therapy » Volume 14

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Total article views   HTML views PDF downloads Totals
4,746 Dovepress* 4,289+ 674 4,963
PubMed Central* 457 210 667
Totals 4,746 884 5,630
*Since 20 April 2021
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar